Literature DB >> 11560967

Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.

C N Sternberg1, M K Parmar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11560967

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Neoadjuvant chemotherapy for bladder cancer.

Authors:  Peter C Black; Gordon A Brown; H Barton Grossman; Colin P Dinney
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.

Authors:  Arlene O Siefker-Radtke; Colin P Dinney; Yu Shen; Dallas L Williams; Ashish M Kamat; H Barton Grossman; Randall E Millikan
Journal:  Cancer       Date:  2012-08-22       Impact factor: 6.860

Review 3.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 4.  Localized and locally advanced bladder cancer.

Authors:  Fabio Calabrò; Cora N Sternberg
Journal:  Curr Treat Options Oncol       Date:  2002-10

5.  Survival from bladder cancer in England and Wales up to 2001.

Authors:  P Whelan
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.